Document Detail


A prospective, multicenter, randomized trial of percutaneous transmyocardial laser revascularization in patients with nonrecanalizable chronic total occlusions.
MedLine Citation:
PMID:  12020483     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: We sought to evaluate the safety and efficacy of percutaneous transmyocardial revascularization (PTMR) in patients with refractory angina caused by one or more chronic total occlusions (CTOs) of a native coronary artery. BACKGROUND: Previous unblinded, randomized trials of PTMR in patients with end-stage coronary artery disease and refractory angina have demonstrated significant relief of angina and increased exercise duration. Whether such benefits would be realized in blinded patients with less extensive coronary artery disease is unknown. METHODS: A total of 141 consecutive patients with class III or IV angina caused by one or more chronically occluded native coronary arteries in which a percutaneous coronary intervention (PCI) had failed were prospectively randomized, at 17 medical centers, in the same procedure, to PTMR plus maximal medical therapy (MMT) (n = 71) or MMT only (n = 70). Blinding was achieved through heavy sedation, dark goggles and the concurrent performance of PCI in all patients. RESULTS: Baseline characteristics were similar between the two groups. A median number of 20 laser channels were created in patients randomized to PTMR. At six months, the anginal class improved by two or more classes in 49% of patients assigned to PTMR and in 37% of those assigned to MMT (p = 0.33). The median increase in exercise duration from baseline to six months was 64 s with PTMR versus 52 s with MMT (p = 0.73). There were no differences in the six-month rates of death (8.6% vs. 8.8%), myocardial infarction (4.3% vs. 2.9%) or any revascularization (4.3% vs. 5.9%) in the PTMR and MMT groups, respectively (p = NS for all). CONCLUSIONS: In patients with class III or IV angina caused by nonrecanalizable CTOs, the performance of PTMR does not result in a greater reduction in angina, improvement in exercise duration or survival free of adverse cardiac events, as compared with MMT only.
Authors:
Gregg W Stone; Paul S Teirstein; Ronald Rubenstein; Dwayne Schmidt; Patrick L Whitlow; Edward J Kosinski; Gregory Mishkel; John A Power
Related Documents :
21455723 - Desmoglein 2 mutant mice develop cardiac fibrosis and dilation.
2330893 - Diagnostic value of ambulatory holter monitoring for the detection of coronary artery d...
20007913 - Short communication: ischemia/reperfusion tolerance is time-of-day-dependent: mediation...
Publication Detail:
Type:  Clinical Trial; Evaluation Studies; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  39     ISSN:  0735-1097     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2002 May 
Date Detail:
Created Date:  2002-05-21     Completed Date:  2002-06-06     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1581-7     Citation Subset:  AIM; IM    
Affiliation:
Cardiovascular Research Foundation, New York, New York 10021, USA. gstone@crf.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angina Pectoris / mortality,  surgery*
Cause of Death
Coronary Disease / mortality,  surgery*
Female
Follow-Up Studies
Heart Ventricles / surgery
Humans
Laser Therapy / methods*
Male
Middle Aged
Myocardial Revascularization / methods*
Prospective Studies
Survival Rate
Comments/Corrections
Comment In:
J Am Coll Cardiol. 2002 Dec 4;40(11):2062; author reply 2062-3   [PMID:  12475472 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Walter Gaskell and the understanding of atrioventricular conduction and block.
Next Document:  Continued symptomatic improvement three to five years after transmyocardial revascularization with C...